Journal of Surgery Concepts & Practice >

2023 , Vol. 28 >Issue 01: 36 - 41

DOI: https://doi.org/10.16139/j.1007-9610.2023.01.06

Experts forum

Summary and prospect of perioperative comprehensive treatment for gastric cancer in China

Expand
  • 1. Department of General Surgery, Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2. Department of Digestive Surgical Oncology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Nanjing 210029, China

Received date: 2022-11-24

  Online published: 2023-03-25

Fold

Abstract

Most of the patients with gastric cancer in China have been at the middle and advanced stages during diagnostic and treatment with poor prognosis overall. Perioperative radiotherapy, chemotherapy, immune therapy and other comprehensive treatment methods for gastric cancer patients preoperative and intraoperation may reduce tumor staging, increase the rate of surgical resection and prolong the time of patient survival. Perioperative comprehensive treatment has developed more than 30 years in China. Many results from relevant research were gotten combined with laying down the consensus and guidelines, and applied to clinic in recent years. With the emergence and development of new technologies and new strategies for comprehensive treatment, perioperative comprehensive treatment and conversion therapy will improve at much extent the rate of survival for gastric cancer patients in China.

Key words： China; Gastric cancer; Perioperation; Comprehensive treatment; Conversion therapy

Cite this article

LIU Wentao, LIU Fukun . Summary and prospect of perioperative comprehensive treatment for gastric cancer in China[J]. Journal of Surgery Concepts & Practice, 2023 , 28(01) : 36 -41 . DOI: 10.16139/j.1007-9610.2023.01.06

References

[1] 徐玮, 刘文韬, 杨秋蒙, 等. 胃癌围手术期治疗现状和新进展[J]. 世界华人消化杂志, 2016, 24(35):4621-4633.
[1] XU W, LIU W T, YANG Q M, et al. Current situation and new advances in perioperative treatment of gastric cancer[J]. World Chinese J Digest, 2016, 24(35):4621-4633.
[2] 刘福坤.肿瘤治疗学基础[M]//陈龙邦, 刘福坤. 循证肿瘤治疗学. 郑州: 郑州大学出版社, 2004:18-35.
[2] LIU F K. Base of Tumor Therapy[M]//CHEN L B, LIU F K. Evidence-based oncology. Zhengzhou: Zhengzhou University Press, 2004:18-35.
[3] 刘福坤, 黎介寿, 臧静, 等. 胃癌患者骨髓转移癌的检测和临床观察[J]. 中华外科杂志, 1995, 23(9):554-556.
[3] LIU F K, LI J S, ZANG J, et al. Detection of micrometastasis in the bone marrow of patients with gastric cancer[J]. Chin J Surg, 1995, 23(9):554-556.
[4] DU S S, CHEN G W, YANG P, et al. Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation[J]. Int J Radiat Oncol Biol Phys, 2022, 112(5):1243-1255.
[5] 刘福坤, 陈忠豪. 胃癌术前介入治疗的临床和病理观察[J]. 南京大学学报(自然科学), 1998, 34(2):167-171.
[5] LIU F K, LI G L, CHEN Z H, et al. Clinical and pathological observation of preoperative interventional therapy for gastric cancer[J]. J Nanjing Univ(Nat Sci), 1998, 34(2):167-171.
[6] 刘福坤, 曹建民. 胃恶性肿瘤术前介入治疗的基础和临床研究[J]. 外科理论与实践, 2000, 5(3):161-162.
[6] LIU F K, CAO J M. Pre-operative transcatheter arterial chemotherapy for gastric malignancies[J]. J Surg Concepts Pract, 2000, 5(3):161-162.
[7] XU W, WANG L, YAN C, et al. Neoadjuvant chemotherapy versus direct surgery for locally advanced gastric cancer with serosal invasion (cT4NxM0): a propensity score-matched analysis[J]. Front Oncol, 2021, 11:718556.
[8] XU W, FAN Z, WANG L, et al. Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer[J]. Am J Transl Res, 2021, 13(3):1568-1579.
[9] ZHANG X, LIANG H, LI Z, et al. Perioperative or post-operative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial[J]. Lancet Oncol, 2021, 22(8):1081-1092.
[10] 中国抗癌协会胃癌专业委员会. 局部进展期胃癌围手术期治疗中国专家共识(2021版)[J]. 中华胃肠外科杂志, 2021, 24(9):741-748.
[10] Gastric Cancer Association, China Anti-Cancer Association. Chinese expert consensus on perioperative treatment of locally advanced gastric cancer (2021 version)[J]. Chin J Gastrointest Surg, 2021, 24(9):741-748.
[11] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)原发性胃癌诊疗指南 2017.V1[M]. 北京: 人民卫生出版社, 2017.
[11] Working Committee of the Guidelines of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of primary gastric cancer 2017.V1[M]. Beijing: People's Health Press, 2021.
[12] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)胃癌诊疗指南2021[M]. 北京: 人民卫生出版社, 2021.
[12] Working Committee of the Guidelines of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Gastric Cancer 2021[M]. Beijing: People's Health Press, 2021.
[13] 马韬, 张俊, 朱正纲. 从CRITICS研究看胃癌围手术期治疗的发展趋势[J]. 中华胃肠外科杂志, 2018, 21(10):1178-1180.
[13] MA T, ZHANG J, ZHU Z G. The development trend of perioperative treatment of gastric cancer from CRITICS study[J]. Chin J Gastrointest Surg, 2018, 21(10):1178-1180.
[14] LIU X, JIN J, CAI H, et al. Study protocol of a rando-mized phase Ⅲ trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT[J]. BMC Cancer, 2019, 19(1):606.
[15] MANEESH K. BEEHARRY, 刘文韬, 燕敏. 胃癌根治术联合腹腔内温热灌注化疗的有效性和安全性[J]. 外科理论与实践, 2018, 23(1):87-90.
[15] MANEESH K. BEEHARRY, LIU W T, YAN M. Effieacy and safety of curative gastrectomy for gastric cancer with hyperthermic intraoperative chemotherapy[J]. J Surg Concepts Pract, 2018, 23(1):87-90.
[16] XU J, JIANG H, PAN Y, et al. LBA53 Sintilimab plus chemotheray(chemo) versus chemo as the first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma(ORIENT-16): first results of a randomized, double-blinded, phase Ⅲ study[EB/OL]. [2022-11-24]. https://doi.org/10.1016/j.annonc.2021.08.2133.
[17] 梁寒. Ⅳ期胃癌转化治疗的研究进展[J]. 中华胃肠外科杂志, 2021, 24(2):107-111.
[17] LIANG H. Progress in conversion therapy for stage Ⅳ gastric cancer[J]. Chin J Gastrointest Surg, 2021, 24(2):107-111.
[18] SONG X H, ZHANG W H, KAI L, et al. Prognostic impact of Borrmann classification on advanced gastric cancer: a retrospective cohort from a single institution in western China[J]. World J Surg Oncol, 2020, 18(1):204.
[19] AMRHEIN V, GREENLAND S, MCSHANE B. Scientists rise up against statistical significance[J]. Nature, 2019, 567(7748):305-307.
[20] 丁学伟, 郑志超, 赵群, 等. 基于多中心真实世界数据的胃癌围手术期化疗患者生存分析[J]. 中华胃肠外科杂志, 2021, 24(5):403-412.
[20] DING X W, ZHENG Z C, ZHAO Q, et al. A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data[J]. Chin J Gastrointest Surg, 2021, 24(5):403-412.
Options
Outlines

/

〈 〉